Jupiter Neurosciences Expands Brain Health Expertise with Nugevia Consumer Supplement Line

Jupiter Neurosciences Inc. is expanding its brain health expertise to consumer markets with Nugevia, a direct-to-consumer longevity product line focused on mitochondrial support, mental clarity, and beauty from within. The clinical-stage pharmaceutical company, known for developing JOTROL™, an enhanced orally administered resveratrol formulation, expects its Nugevia MND cognitive health supplement to account for approximately 60% of company sales by volume. This strategic move represents a natural extension of the company's neuroscience foundation into the rapidly growing consumer wellness space.

The global brain health supplement market is projected to reach about $23 billion by 2030, growing at a compound annual growth rate of around 13% between now and then. This growth is driven by aging populations worldwide seeking to maintain mental clarity, concentration, and overall cognitive function as they live longer. Jupiter Neurosciences positions its Nugevia MND formulation as building directly on the company's pharmaceutical expertise in neuroinflammation and central nervous system function, addressing the same biological pathways that define both aging and cognition.

At the core of Jupiter Neurosciences' technology is JOTROL, which the company describes as a first-in-class oral therapeutic that reaches effective levels in the brain. The formulation delivers approximately nine times higher absorption than naive resveratrol and demonstrates proven central nervous system penetration. JOTROL increases energy metabolism, induces mitochondrial biogenesis, and reduces inflammation while activating PARP-1, an important protein in DNA repair and stress response. Phase one trials determined the drug was safe and well-tolerated at all dose levels and demonstrated blood plasma levels 8-10-fold higher than historical clinical trials with naive resveratrol.

What distinguishes Nugevia from single-ingredient supplements is its precision-engineered intelligent stacking of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. The supplement line includes Nugevia MND for cognitive function, Nugevia GLO, and Nugevia PWR. The company has secured patents for JOTROL in the United States, Europe, China, Hong Kong, and Japan, with protection extending through 2036.

To promote its consumer products, Jupiter Neurosciences has engaged multiple scientists and brand ambassadors representing different audience segments. These include former tennis champion Annika Sörenstam, NBA legend Chris Webber, scientist Charbel Moussa, and biohacker Jean Fallacar, all of whom reportedly use Nugevia in their daily lives. The company emphasizes that its entry into the supplement space comes from clinical research rather than traditional consumer product development, creating what it describes as a dual-path strategy of advancing prescription therapies while providing evidence-based solutions for healthy aging.